Created at	Source	Raw Value	Validated value
April 20, 2022, 12:30 a.m.	usa	Geometric Mean Titer (GMT) of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain;GMT of mRNA-1273.214 and mRNA-1273 Against the B1.1.529 Strain;GMT of mRNA-1273.214 and mRNA-1273 Against the Prototype Strain;Number of Participants with AEs Leading to Withdrawal;Number of Participants with AEs of Special Interest (AESIs);Number of Participants with Medically Attended AEs (MAAEs);Number of Participants with Serious AEs (SAEs);Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs)	Geometric Mean Titer (GMT) of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain;GMT of mRNA-1273.214 and mRNA-1273 Against the B1.1.529 Strain;GMT of mRNA-1273.214 and mRNA-1273 Against the Prototype Strain;Number of Participants with AEs Leading to Withdrawal;Number of Participants with AEs of Special Interest (AESIs);Number of Participants with Medically Attended AEs (MAAEs);Number of Participants with Serious AEs (SAEs);Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs)
Feb. 23, 2022, 6:30 p.m.	usa	Geometric Mean Fold Rise (GMFR) of mRNA-1273.529 Against the B.1.1.529 Strain;Geometric Mean Titer (GMT) of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 29 After Study Vaccine Administration;Number of Participants with AEs Leading to Withdrawal;Number of Participants with AEs of Special Interest (AESIs);Number of Participants with Medically Attended AEs (MAAEs);Number of Participants with Serious AEs (SAEs);Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs)	Geometric Mean Fold Rise (GMFR) of mRNA-1273.529 Against the B.1.1.529 Strain;Geometric Mean Titer (GMT) of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 29 After Study Vaccine Administration;Number of Participants with AEs Leading to Withdrawal;Number of Participants with AEs of Special Interest (AESIs);Number of Participants with Medically Attended AEs (MAAEs);Number of Participants with Serious AEs (SAEs);Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs)